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Background: Cancer-related fatigue (CRF) is a common and often long-lasting symptom for many breast cancer
survivors. Evidence for its management is scarce. However, the Traditional Chinese Medicine (TCM) Shu Gan Jian Pi
(SGJP) granules is an effective and practical therapy for CRF.
Methods/Design: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to
determine whether the SGJP granules can effectively manage CRF. Breast cancer survivors experiencing fatigue
within 5 years of primary treatment completion will be enrolled and randomly assigned to Group S (SGJP) or
Group P (placebo). The primary outcome measures will include Revised Piper Fatigue Scale score. Outcome measures
will be collected at baseline and at weeks 2, 4, and 8.
Discussion: This study’s findings may contribute to the development of an effective intervention for CRF.
Trial registration: Current controlled trials ISRCTN12702489, 14 August, 2013.
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Cancer-related fatigue (CRF) has been documented as
one of the most distressing symptoms of breast cancer
survivors [1]. It is defined as a distressing, persistent,
subjective sense of physical, emotional, and/or cognitive
feeling of tiredness or exhaustion related to cancer or
cancer treatment that is not proportional to recent acti-
vity and interferes with usual functioning [2]. Prevalence
rates for CRF of breast cancer are reportedly 58 to
94% during treatment and between 56% and 95% after
adjuvant chemotherapy [1]. Cancer survivors frequently
report that they never regain their pre-diagnostic energy
level, which diminishes their quality of life [3]. Many
common problems experienced by breast cancer survi-
vors may be associated with CRF [4]. Problems asso-
ciated with fatigue may be the result of the cancer itself,* Correspondence: wangxiaomin_bhtcm@126.com
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The pathogenesis of CRF has not been thoroughly described
and several mechanisms can contribute to its development.
Non-pharmacological measures that have shown promise
include education, cognitive-behavioral therapy, exercise,
and sleep therapy [1,7]. Pharmacological measures that have
shown potential include the psycho-stimulants methyl-
phenidate, dexmethylphenidate, erythropoietin, darbepoe-
tin, progestational steroids (medroxyprogesterone acetate,
megestrol acetate), modafinil, and paroxetine [1,7]. How-
ever, only small differences were noted between pharma-
cological treatments and placebo.
Traditional Chinese Medicine (TCM) is one of the most
common interventions used in China. Shu Gan Jian Pi
(SGJP) was changed from the classical formula Xiao Yao
San that was derived from Taiping Huimin Heji Ju Fang,
which was originally compiled by the government of the
Han dynasty. CRF belongs to the syndrome of liver qi
stagnation and splenic qi asthenia in TCM rationale. The
liver possesses the physiological functions of dredging andis an Open Access article distributed under the terms of the Creative Commons
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tion of qi due to emotional depression results in breast
cancer patients manifesting emotional depression and mi-
gratory pain in the chest. If the liver fails to dredge and
disperse,the liver will invades the spleen, it will cause dys-
function of the muscles of the four limbs. Thus, breast
cancer patients manifest fatigue.
SGJP granules can relieve the syndrome; SGJP is com-
posed of six herbs including Radix astragali (Huang Qi),
Radix bupleuri (Chai Hu), Radix angelicae alba (Dang
Gui), and three other herbs. The action of Radix astrag-
ali (Huang Qi) is to replenish qi. That of Radix bupleuri
(Chai Hu) is to disperse the stagnated liver-qi. Four
other herbs have the same actions. Many patients in
China turn to TCM with the complaint of fatigue after
cancer treatment. One study reported that TCM demon-
strated the ability to relieve CRF [8]. We have attempted
to treat CRF in clinical practice without success. Al-
though SGJP granules have demonstrated positive effects
on relieving CRF, rigid validation using a randomized
controlled trial remains the best way to examine the ef-
fects of SGJP in patients.
Methods/Design
Study design
This study will use a two-group multicenter, rando-
mized, double-blind, and placebo-controlled clinical trial
design in which participants will receive either enhanced
TCM or placebo. We will enroll 118 patients with breast
cancer. Participants will be recruited from three centers:
Beijing Hospital of Traditional Chinese Medicine, Beijing
Cancer Hospital, and People’s Hospital of Beijing Da
Xing District. The study schema and estimated recruit-
ment numbers are presented in Figure 1. Randomization
will be used to allocate patients to groups subjected to a
4-week treatment period and a 4-week follow-up period.
Four visits will be scheduled for each patient: baseline
and weeks 2, 4, and 8.
Ethical issues
The study received ethical approval from the Research
Ethical Committee of Beijing Hospital of Traditional
Chinese Medicine Affiliated with Capital Medical University
(number 201338) and registered with the International
Standard Randomized Controlled Trial Number Register
(ISRCTN 12702489). Patients willing to participate will
sign a consent form prior to participating.
Setting and patients
The study will include breast cancer patients with the
complaint of moderate to severe fatigue. Patients will be
screened for fatigue using the Revised Piper Fatigue
Scale (RPFS) to identify those with significant fatigue.
Table 1 will show the detailed eligibility and exclusioncriteria. Recruitment will occur at three centers in Beijing:
Beijing Hospital of Traditional Chinese Medicine, Beijing
Cancer Hospital, and People’s Hospital of Beijing Da Xing
District.Intervention
If patients meet the inclusion criteria, they will take a
randomly generated number to the pharmacy and the
pharmacist will give them SGJP or placebo in a package
containing either 15.75 mg medication or dextrin (90%)
and Herba pogostemonis (10%). Patients will take one
package twice daily. The intervention period will be over
4 weeks. After 4 weeks on the prescribed medication,
the patients will stop taking SGJP or placebo for another
4 weeks and then undergo the clinical evaluation.
The intervention group treatment is composed of six
herbs including Radix astragali (Huang Qi), Radix bupleuri
(Chai Hu), Radix angelicae alba (Dang Gui), and three
other herbs. The ingredients of SGJP cannot be disclosed
because the formula is currently being patented. The con-
trol group formulation includes dextrin (90%) and Herba
pogostemonis (10%). The study medicine was made by
Beijing Tcmages Pharmaceutical Co., LTD, Beijing, China.
Based on the infrared fingerprint spectrum techniques and
Good Manufacturing Practices (GMP) full range manage-
ment, this company can guarantee the consistency of
granule composition.Assessment
Primary outcome measure
Revised Piper Fatigue Scale (RPFS), a multidimensional as-
sessment tool that subjectively measures the level of fa-
tigue of patients with cancer, has been widely used in
research. It consists of 22 items, each rated on a visual
analog scale with a score ranging from 0 (least) to 10
(most). The items are divided into four dimensions: seve-
rity, affective meaning, sensory, and cognition [9].Secondary outcome measure
Eastern Cooperative Oncology Group Performance Status
(ECOG-PS) is a scale to evaluate performance status. It
is based on five levels [10].
The Self-Rating Scale of Sleep (SRSS) is a frequently-
used instrument in China that consists of 10 items that
measure sleep quality. Each item is rated on a scale of 1
(best status) to 5 (worst status) [11].
The Hospital Anxiety and Depression Scale (HADS)
was developed to identify anxiety disorders and depres-
sion among patients. It is divided into an Anxiety sub-
scale and a Depression subscale, both of which contain
seven intermingled items. Each item is rated on a scale
of 0 (best status) to 3 (worst status) [9].
Figure 1 Flow of patients through the trial. 1. RPFS: Revised Piper Fatigue Scale. 2. ECOG-PS: Eastern Cooperative Oncology Group Performance
Status. 3. SRSS: Self-Rating Scale of Sleep. 4. HADS: Hospital Anxiety and Depression Scale. 5. Safety assessment: routine blood test, routine feces
test, routine urine test, liver and kidney function tests and electrocardiogram.
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To assess the safety of SGJP, we will perform the follo-
wing tests on participants at the screening phase (base-
line) and after treatment (week 8): routine blood, routine
feces, routine urine, liver and kidney function, and
electrocardiography.
Sample size
Based on our previous study, we have baseline data from
Chinese breast cancer patients with CRF in Beijing,
China [12]. Although the study was published in a
Chinese journal, we considered it is the most factual
data. RPFS was the primary outcome in our previous
study. The planned sample size is 118 patients with an
anticipated 15% attrition rate. With this sample size,there will be in excess of a 95% power and a (1-side) 5%
significance level in detecting treatment differences. The
standard deviation is 1.27. The study was planned to de-
tect a one-unit difference in change scores between the
two groups.
Randomization and blinding
Eligible patients will be randomized into the groups SGJP
and placebo (P) in a 1:1 ratio for a target total of 118 pa-
tients. Patients will be randomized in blocks of four by
Statistical Analysis System (SAS). This will be a double-
blind study in which the participants and investigators are
blinded. The patients will receive granules either with
SGJP or placebo. These granules have the same taste, ap-
pearance, and color.
Table 2 Study visits
Visit 1 Visit 2 Visit 3 Follow-up




RPFS × × × ×
ECOG-PS × × × ×
SRSS × × × ×
HADS × × × ×
Safety assessment × ×
Adverse events × × ×
Combined medication × × ×
Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance
Status; HADS, Hospital Anxiety and Depression Scale; RPFS, Revised Piper Fatigue
Scale; SRSS, Self-Rating Scale of Sleep.
Table 1 Eligibility criteria for the randomized clinical trial
Inclusion criteria
1 Patients have definite outpatient pathologic diagnosis of breast cancer
2 Eligible patients had completed chemotherapy and/or radiotherapy
at least 1 month and mastectomy within 5 years
3 Stage I to III breast cancer with no evidence of recurrence and metastasis
4 Eastern Cooperative Oncology Group Performance Status 0 to 2
5 Traditional Chinese Medicine (TCM) syndrome is differentiated as liver
depression and spleen deficiency
6 Anticipated survival time exceeds 6 months
7 Eligible patients have no plan to receive chemotherapy and/or
radiotherapy during the study
8 Revised Piper Fatigue Scale score ≥ 4
9 Provided signed informed consent before enrollment
Exclusion criteria
1 Complicated by serious diseases of heart, liver and kidney, immune
and hematopoietic systems
2 Children and pregnancy
3 Receiving active treatment for anemia with erythropoietin or blood
transfusions
4 Using steroids to cure cancer-related fatigue
5 Diagnosed with depression, mental disease or cognitive impairment
6 Allergic to a Chinese herbal compound
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Statistical analyses will be performed by the Statistical
Package for Social Science statistics (SPSS 18.0). Conti-
nuous variables will be expressed as median and standard
deviations. Groups will be compared using the t-test or
Student’s t-test, as appropriate, based on the data distribu-
tion. Categorical variables will be expressed as percen-
tages. Groups will be compared using the chi-square or
Fisher’s exact test, as appropriate, based on the expected
counts. Patient characteristics and past history will be re-
ported and compared between groups. Descriptive sta-
tistics will be presented to describe the trial results.
Student’s t-test will be applied to fatigue change scores
at every time point between the groups. Similar analyses
will be performed for other outcomes (ECOG-PS, SRSS,
HADS). Values of P < 0.05 will be considered statistically
significant.
Data collection
We will collect basic data from each patient including
their characteristics and past history of cancer, out-
comes, and safety assessment data at baseline and follow
them up at 2, 4, and 8 weeks (Table 2).
Serious adverse event reporting and monitoring
Any serious adverse events deemed to be related to the
intervention or due to study participation will be re-
ported to the chief investigator within 24 hours. BeijingQihuang Medicine Clinical Research Center will be re-
sponsible for quality control.
Discussion
CRF is a significant problem in as many as 40% of
disease-free patients and impacts their quality of life.
The National Comprehensive Cancer Network provides
an evidence-based guideline that include pharmaco-
logical and non-pharmacological interventions [2]. How-
ever, it does not include TCM, which effectively relieves
the symptoms of CRF. This trial will explore its effec-
tiveness as an intervention to support patients with
breast cancer and CRF. To our knowledge, this will be
the first Chinese herbal formula intervention designed to
reduce CRF. This study has the potential to contribute
to the development of an effective intervention to help
relieve CRF.
Our study also has several limitations that require con-
sideration. First, we did not design subjective measures to
assess CRF changes. Metrics for both subjective and objec-
tive measures, including inflammatory and genetic markers,
are recommended [1]. Second, the primary outcome RPFS
is not often used in clinical research with breast cancer
patients. Many questionnaires for CRF use a single-
dimensional or multidimensional perspective [13]. How-
ever, there is no acknowledged questionnaire. We hope we
can improve on these problems in future research.
Trial status
We are currently recruiting participants.
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